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Platelet-derived growth factor is a cofactor in 
the induction of 1 (I) procollagen expression 
by transforming growth factor-131 in smooth 
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and Seoul, South Korea 
Purpose: Depending on the derivation of vascular smooth muscle cells (SMC), transform- 
ing growth factor-J31 (TGF-[31) has variable effects on proliferation and expression of 
extracellular matrix. Relatively little is known about TGF-]31's effects on human arterial 
SMC. Therefore, we sought o determine the effects of TGF-]31 on human arterial SMC 
proliferation and la( I)  procollagen expression. The mechanisms by which TGF-J31 
regulate type I procollagen expression were also investigated. 
Methods: SMC cultures were established from the aorta of transplant donors. Serial doses 
of TGF-}I were applied, and cellular proliferation assessed by cell counting and tritiated 
thymidine incorporation. Total cellular ibonucleic acid (RNA) was analyzed by reverse 
transcription-polymerase chain reaction and Northern blot for changes in l(x(I) procol- 
lagen and platelet-derived growth factor (PDGF)-A transcripts. 
Results: In a dose-dependent manner, TGF-[31 inhibited SMC proliferation despite arly 
induction of PDGF-A mRNA. After a delay of 24 hours, TGF-]31 increased 1~(I) 
procollagen expression by 36% compared with control. PDGF-neutralizing antibodies 
blocked the TGF-]~ 1-mediated upregulation of type I procollagen, although PDGF alone 
had no effect on matrix expression. 
Conclusion: The results indicate that TGF-[31 is a potent inhibitor of human arterial SMC 
proliferation that has a moderate effect on la(I)  procoUagen transcripts. Despite inducing 
PDGF-A gene expression, TGF-[31 is not a mitogen in adult human arterial SMC. TGF-]31 
regulates SMC type I procoUagen expression partly by inducing PDGF-A as a co-factor. 
(J Vasc Surg 1996;23:767-74.) 
Arterial smooth muscle cells (SMC) play a central 
role in the pathogenesis ofatherosclerosis and neoin- 
timal hyperplasia. Key pathologic events in this pro- 
cess include SMC migration from the tunica media, 
proliferation, and secretion of excess matrix proteins.1 
This accumulation of extracellular connective tissue, 
consisting primarily of fibrillar collagens, leads to 
plaque progression and luminal stenosis. 2 
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Cytoldnes produced by locally invasive inflamma- 
tory cells are intimately involved in modulating SMC 
dysregulation. Of the variety of cytokines tudied in 
vascular disease, the [3-1 isoform of transforming 
growth factor (TGF-~I) has been implicated in the 
pathogenesis of both atherosclerosis and intimal hy- 
perplasia) '4Numerous investigators have examined 
the effects of TGF-~I on SMC proliferation, report- 
ing both inhibition and stimulation ofproliferation.'~-7 
The clinical relevance of these studies to disease in 
human beings may be limited because these model 
systems have used either neonatal or animal SMC. We 
have previously demonstrated that TGF-[31 has no 
mitogenic effect on human arterial smooth muscle 
cells. 8 
Although SMC hyperplasia has an important role 
in the initial development of arterial occlusive disease 
and restenosis after bypass or angioplasty, the bulk of 
the lesion that compromises the lumen is extracellular 
connective tissue. The predominant matrix protein is 
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Table I. Sequence of oligonucleotides primers and probes for RT-PCR 
GAPDH Sense 
Antisense 
Probe 
Type I collagen Sense 
Antisense 
Probe 
PDGF (A chain) Sense 
Antisense 
Probe 
5'-CCATGGAGAAGGCTGGGG-3' 
5'-CAAAGTTGTCATGGATGACC-3' 
5'-CTGCACCACCAACTGCTTAGC-3' 
5'-ACGTGATCTGTGACGAGACC-3' 
5'-AGCAARGTTTCCTCCGAGGC-3' 
5'TTGGGTCCCTCGACGCCGGTGGTTTCTTG 
GTCGGTGGGTGACTCT-3' 
5'-CAGTCAGATCCACAGCATCC-3' 
5'-AATGACCGTCCTGGTCTTGC-3' 
5'-GAGCTCTCAGGCTGGTGTCC-3' 
GAPDH, Glyceraldehyde-3-phosphate dehydrogenase. 
type I collagen. TGF-[31 is reported to be a potent 
fibrogenic peptide in mesenchymal cells 9 and has been 
implicated in numerous fibrotic diseases, l° Despite 
this, the effects of TGF-[31 on procollagen gene 
expression in human arterial SMC have not been 
investigated. The purposes of our study were to (1) 
further investigate and characterize the effects of 
TGF-[31 on human arterial SMC proliferation, (2) 
determine the effects of TGF-[31 on human arterial 
SMC 10t(I) procollagen expression, and (3) study the 
mechanisms by which TGF-]31 regulates 10~(I) pro- 
collagen gene expression i  these SMC. 
MATERIAL AND METHODS 
SMC culture. SMC were isolated from the infra- 
renal aorta of transplant donors (n = 5) by enzymatic 
digestion as previously described, s Cultured cells 
were maintained in culture in M-199 supplemented 
with 10% fetal bovine serum and were used for 
experiments during the second through fourth pas- 
sages. SMC identity was verified by the appearance of
"hill and valley" formation under phase-contrast 
microscopy and by immunohistochemical staining 
with antibodies pecific for SMC ~-actin. 
Proliferation assays. SMC were plated in multi- 
well dishes in M-199 with 10% fetal bovine serum 
(0.4x 104 cells/cm 2) and then incubated with 
TGF-~I at doses of 0.1, 1.0, and 10.0 ng/ml. Daily 
cell counts were performed by trypsinization and 
Coulter counting. 8 Cellular deoxyribonucleic acid 
(DNA) synthesis was determined by tritiated thymi- 
dine incorporation. Subconfluent cells were serum- 
deprived for 72 hours before TGF-[31 treatment, then 
assayed every 12 hours. Media were aspirated and 
replaced with M-199 supplemented with 1 btCi/ml 
titrated thymidinc (Amersham Life Science, Arling- 
ton Heights, Ill.) for a 2-hour incubation. The cells 
were thcn fixed with 1 ml ice-cold 5% trichloroacetic 
acid. The precipitate was then solubilized in 0.25 N 
sodium hydroxide and subsequently neutralized in 
1 N hydrochloric acid. Samples were then counted by 
a ]3-scintillation counter. 
Ribonucleie acid (RNA) analysis. Total cellular 
RNA was extracted from SMC with Trizol (Gibco 
BRL, Gaithersburg, Md.). For Northern blot analy- 
sis, 10 btg RNA was fractionated in formaldehyde- 
agarose gels, transferred to nylon membranes, and 
hybridized with 32p-labeled probes as previously de- 
scribed. II Dot blots were made with 5 gg RIGA. For 
reverse transcription-polymerase chain reaction 
(RT-PCR) of total cellular RNA, 0.25 btg RNA was 
reverse-transcribed with Superscript RT (Gibco B RL) 
and the cDNA amplifed 20 cycles with Taq poly- 
merase (Promega, Madison, Wis.) with sense and 
antisense oligonucleotide primers, eDNA products 
(20 btl) were fractionated on 2% agarose gels, trans- 
ferred to nylon membranes, and hybridized with 
32p-labeled probes for autoradiography. Blot signals 
were quantified irectly by a Phosphor-Imager (Mo- 
lecular Dynamics, Sunnyvale, Calif.). 
Cytokines, antibodies, and oligonucleotides. 
Recombinant human TGF-131, platelet-derived 
growth factor (PDGF)-AB cytokines, and antihuman 
PDGF neutralizing antibody were purchased from 
R&D Systems (Minneapolis, Minn.). The anti-PDGF 
IgG readily neutralizcs natural human PDGF, 
rhPDGF-AB, and rhPDGF-BB isoforms and in excess 
will neutralize rhPDGF-AA. Antimuscle actin IgG 
(Enzo Diagnostics, New York, N.Y.) was used for 
SMC c~-actin immunochemical staining. RT-PCR 
deoxyribonucleotides (Table I) were synthesized and 
purified by UNMC Molecular Biology Core Lab 
(Omaha, Neb.). 
Statistical analysis. SMC proliferation assays 
were performed in triplicate wells for each group, and 
results were expressed as the mean + SD. Groups 
were compared by analysis of variance. The signals for 
procollagen and PDGF-A mRNA levels were normal- 
ized to their glyceraldehyde-3-phosphate dehydroge- 
nase signals and expressed as the mean + SEM and 
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Fig. 1. Subconfluent human arterial SMC were treated with varying concentrations of rh 
TGF-[31 and cells counted every 24 hours. Results represent mean + SD of triplicate samples. 
High-dose TGF-131 (1.0 and 10.0 ng/ml) inhibited SMC proliferation at 48 hours (*, 1.0 and 
10.0 ng/ml < control; p < 0.05), and at 72 and 96 hours (**, 1.0 and 10.0 ng/mt < control and 
0.1 ng/ml; p < 0.05). Low-dose TGF-i31 exhibited a transient inhibitory effect at 48 hours 
compared with control (p < 0.05), but did not differ from control at 72 and 96 hours. 
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Fig. 2. Human arterial SMC proliferation as measured by tritiated thymidine incorporation was 
inhibited by all doses of TGF-[31 at 24 hours (*, p < 0.001), and by high-dose TGF-[~I (h0 and 
10.0 ng/ml) at 48 hours (**, p < 0.005). Data represent mean _+ SD of triplicate samples. 
compared by analysis of variance. Differences were 
considered significant when p < 0.05. 
RESULTS 
TGF-[~I inhibits SMC prol i feration in a dose- 
dependent fashion. TGF-[31 induces SMC growth 
arrest in a dose-dependent manner (Fig. 1). Cell 
counting demonstrates that after 48 hours of incuba- 
tion with TGF-[31, all doses of TGF-[31 inhibited 
growth compared with control. At 72 and 96 hours, 
only the higher doses of TGF-~I  (1.0 and 10.0 
ng/ml )  continued to inhibit growth, whereas cellular 
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Fig. 3. Subconfluent human arterial SMC were treated 
with 10 ng/ml TGF-]31 and RNA analyzed by RT-PCR for 
ltx(I) procollagen and glyceraldehyde-3-phosphate de- 
hydrogenase. Enhanced expression of type I collagen 
mRNA did not occur until 24 and 48 hours after TGF-[31 
treatment. 
proliferation in low-dose TGF-[31 (0.1 ng/ml) was 
not different from the untreated SMC. These findings 
were corroborated by tritiatcd thymidine uptake assay 
(Fig. 2). At 24 hours, all doses of TGF-131 significantly 
inhibited tritiated thymidine incorporation into 
newly synthesizing DNA. Thc control cells at later 
timc points exhibited iminished thymidine uptake, 
which rcflected the lowcr numbcr of cclls that were 
synchronously replicating. There was a trend toward 
continued inhibition ofthymidine uptake at 36 hours 
with thc 1.0 and 10.0 ng/ml doses ofTGF-131. By 48 
hours, thc high doses of TGF-131 continued to inhibit 
thymidine incorporation, but the low dose (0.1 
ng/ml) of TGF-[3I did not differ from control. Thesc 
data demonstratcd that although all doses of TGF-131 
initially inhibited SMC proliferation, the inhibitory 
effect was transient at the lowest dose ofTGF- 131 (0.1 
ng/ml) and sustained at higher doses (1.0 and 10.0 
ng/ml). Additional experiments on two other SMC 
cell lines from different donors demonstrated he
same inhibitory effect. 
TGF-[31 stimulates a delayed increase in SMC 
10~(I) procollagen mRNA. Human arterial SMC 
were treated with 10 ng/ml TGF-131 for 48 hours, 
and total cellular RNA was extracted. By RT-PCR, 
type I procollagen (COL1A1) was found to be 
significantly elevated at 24 and 48 hours (Fig. 3). On 
the basis of oligo primer design and affinity, the 
appropriate-sized PCR products of 220 and 260 base 
pairs were observed. Thus TGF-131 mediated upregu- 
lation of 10~(I) procollagen expression in a delayed 
fashion. This increase in mRNA transcripts was also 
dose dependent (Fig. 4). Subsequent Northern blot 
analysis confirmed the time-delayed upregulation 
(data not shown), which was calculated by dot blot 
analysis to be a 36% increase compared with untreated 
Fig. 4. Southern blot analysis of RT-PCR products for 
type I collagen (COL1A1) and glyceraldehyde-3-phos- 
phate dehydrogenase demonstrated dose-related increase in
1 ct(I) procollagen expression with increasing TGF-]31 levels 
at 24 hours. 
SMC (Fig. 5). Delayed procollagcn upregulation by 
TGF-131 was observed in two additional SMC lines 
from different donors. 
TGF-131 induces SMC PDGF-A gene expres- 
sion. PDGF is constitutively expressed at very low 
levels by human arterial SMC in culture. Treatment 
with TGF- ~ 1 ( 10 ng/ml) induced early and sustained 
expression of PDGF-A transcripts (Fig. 6). 
PDGF-AB antibodies prevent he TGF-131 in- 
crease in lcffI) procollagen. Human arterial SMC 
treated with recombinant human PDGF-AB isoform 
(20 ng/ml) did not significantly increase lc~(I) pro- 
collagen expression at 6, 12, or 24 hours (data not 
shown). SMC incubated with 10 ng/ml TGF-131 and 
increasing doses ofanti-PDGF antibody for 36 hours 
showed adose- dependent inhibition of 1 c*(I) procol- 
lagen expression. Thus the TGF-131 stimulation of 
1¢~(I) procollagen was attenuated by PDGF antibod- 
ies (Fig. 7). 
DISCUSSION 
Interpreting the r sults of available information 
about the in vitro effects of TGF-131 on SMC in the 
context of human disease is difficult. These effects 
appear to vary greatly depending on the derivation of 
the SMC (human vs nonhuman, adult vs fetal). 
Furthermore, although it has been suggested that 
TGF-131 induces a phenotypic modulation in SMC, 
the relation between changes in matrix expression and 
proliferation has not been elucidated. By using adult 
human arterial SMC, we sought to determine the 
effects of TGF-131 on cell proliferation and its effects 
on the expression of the major matrix protein in 
plaque, type I procollagen. Our results demonstrated 
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Fig. 5. Arterial SMC were treated with TGF-[~I for 36 hours and total cellular RNA subjected 
to dot blot analysis and signal quantification. Membranes were sequentially probed for 1~(I) 
procollagen and glyceraldehyde-3-phosphate dehydrogenase for normalization. TGF-~31 stimu- 
lated 36% increase in type I collagen expression (3.75 _+ 0.11) compared with control group 
(2.78 _+ 0.32; *, p < 0.05). 
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Fig. 6. Human arterial SMC were treated with TGF-[31 (10 ng/ml), and RNA was reverse- 
transcribed and amplified (20 cycles PCR) by PDGF-A and glyceraldehyde-3-phosphate 
dehydrogenase oligonucleotide primers. Southern blot analysis of eDNA shows PDGF-A is 
constitutively expressed at very low levels and TGF-[31 induces early and sustained increase in 
PDGF-A mRNA. 
that SMC proliferation is potently inhibited by 
TGF-[31 in a dose-dependent manner. TGF-[31 also 
induces a moderate dose-dependent and delayed 
increase in 10~(I) procollagen expression. In addition, 
TGF-[31 causes early upregulation of PDGF-A 
mRNA. PDGF-blocldng antibodies are able to par- 
tially inhibit the TGF-[31-mediated increase in type I
collagen mRNA. 
TGF-[31 has been shown to have varying effects on 
SMC proliferation. Several investigators have found 
TGF-[31 to be mitogenic, 6 7,12 whereas others have 
observed a growth-inhibitory response. <s'13 These 
contradictory effects of TGF-[31 appear to depend on 
the derivation of the SMC, the culture conditions, 
and the presence of other growth-regulatory factors. 
We have recently reported that TGF-[31 inhibits 
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Fig. 7. Subconfluent human arterial SMC were treated 
with TGF-131 (10 ng/ml) and increasing doses of 
PDGF-AB neutralizing antibodies. RNA was extracted after 
36 hours and analyzed by RT-PCR. TGF-[31 stimulation of 
type I procollagen expression is diminished with increasing 
doses of anti-PDGF-AB. 
mitosis in human arterial SMC in a manner that is 
inversely proportional to the rate of cell proliferation. 
In this study we provide further evidence for the 
inhibitory effects of TGF-[31 and demonstrate hat 
this occurs in a dose-dependent fashion. 
Battegay et al. 7 have proposed that the growth- 
regulatory effects of TGF-[31 are moderated through 
its effects on PDGF-A and the PDGF receptor. In 
neonatal SMC, they observed that TGF-[31 upregu- 
lated PDGF-A, which we also found in adult human 
SMC. They also determined that TGF-[31 decreases 
PDGF receptor expression and function. When Bat- 
tegay et al. exposed neonatal human aortic SMC to 
the same doses per cell ofTGF-131, that we used in our 
study, they found TGF-[31 to have mitogenic activity 
comparable with PDGF-AB. We did not find TGF-131 
to be mitogenic at any dose in adult aortic SMC. In 
fact, at physiologic doses of 1.0 ng/ml and 10 ng/ml, 
TGF-[31 is a potent inhibitor of SMC proliferation 
despite the early induction of PDGF-A expression) 4 
This marked difference noted in TGF-[31's effects 
between our study at that ofBattegay etal. may relate 
to SMC derivation--neonatal versus adult aorta. In 
SMC derived from adult human veins, Mii et al.13 also 
found that TGF-[31 inhibited SMC proliferation i a 
dose-dependent manner. 
The primary pathologic feature of clinically sig- 
nificant atherosclerosis and neointimal hyperplasia s
the accumulation of extracellular connective tissue, 
consisting mostly of collagen, fibronectin, and pro- 
teoglycans. These are products of the arterial SMC 
under the influence of inflammatory mediators.1 The 
majority of this extracellular matrix is fibrillar col- 
lagen, primarily type I. In mesenchymal ce ls, TGF-131 
is a potent fibrogenic peptide that plays a pathogenic 
role in diseases such as pulmonary and hepatic fibro- 
sis) ° We have demonstrated that TGF-[~I induces a 
small, dose-dependent increase in lcz(I) procollagen 
gene expression. The effects of TGF-[31 on procol- 
lagen expression and collagen synthesis by vascular 
SMC are variable, with some investigators reporting 
increases is whereas others detect no change. 16 We 
believe these discrepancies in the literature may be 
explained by our finding of delayed upregulation of
procollagen after 24 to 48 hours. That is, the effects 
of TGF-131 on procollagen expression will be missed 
when assessed within the first 24 hours after TGF-[31 
exposure. 
The delayed upregulation fprocollagen prompt- 
ed us to consider that the effects of TGF-131 on 
procollagen gene expression might be mediated 
through synthesis of an intermediary protein. Since 
PDGF has been reported to increase the synthesis of 
other fibrillar collagens in SMC 17 and TGF-[31 in- 
duced PDGF expression within six hours of expo- 
sure, we designed experiments o assess the role of 
PDGF as the mediator of TGF-131 procollagen up- 
regulation. We demonstrated that while PDGF-AB 
did not directly increase SMC 10~(I) procollagen 
mRNA, PDGF-AB neutralizing antibodies were able 
to attenuate TGF-[31's ability to upregulate 10~(I) 
procollagen gene expression. Taken together, these 
data suggest hat PDGF is a co-factor in the in- 
creased procollagen expression that results from 
TGF-[31 exposure (Fig. 8). 
Although the mechanisms responsible for TGF- 
[3 l's effects on SMC proliferation and matrix produc- 
tion have not been elucidated, the temporal relation 
between these changes uggests a common pathway. 
That is, TGF-[31 does not affect either procollagen 
expression or cell growth until 24 hours after expo- 
sure. Matrix synthesis may possibly have a direct 
inhibitory effect or perhaps an i direct effect hrough 
its ability to bind growth factors. The presence of 
circulating levels of activated TGF-[3114 and its detec- 
tion in atherosclerotic and restenotic lesions 3 suggest 
it may have a functional role in regulating SMC. Our 
data suggest that this role may be to exert a homeo- 
static effect on SMC in the normal artery. If the SMC 
from diseased vessels exhibits the same response to 
TGF-131 as the normal SMC, TGF-[31 may be impor- 
tant in the conversion of hyperplastic SMC to a 
synthetic phenotype. 
In summary, we have examined the effects of 
TGF-[31 on proliferation and matrix expression i  the 
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Fig. 8. Proposed role of PDGF-A in TGF-J31-mediated 1~(I) procollagen upregulation i  
human arterial SMC. TGF-~I  induces expression ofPDGF-A mRNA and consequently increases 
PDGF-AA and PDGF-AB protein levels. Because neutralizing antibodies to PDGF attenuate 
TGF-131-mediated procollagen expression, PDGF likely acts as co-factor to promote increased 
procollagen gene expression. 
human arterial SMC. We find TGFq31 to be a potent 
inhibitor of SMC proliferation despite induction of 
the mitogen PDGF-A. In a delayed manner, TGF-~31 
also increases ltx(I) procollagen gene expression. 
PDGF appears to be a co-factor in this regulation of 
SMC procollagen expression. Although little is un- 
derstood about he effects of TGF-~I in the patho- 
genesis and progression of vascular disease, the pres- 
ence of TGF-[31 in serum and its immunohistologic 
identification i  vascular lesions suggests it may have 
an important role. On the basis of our in vitro studies 
with normal SMC, we believe that TGF-[31 may have 
a homeostatic role in maintaining the normal artery. 
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DISCUSSION 
Dr. Gregorio A. Sicard (St. Louis, Mo.). The premise 
of this study is that growth factors PDGF and TGF-]31 are 
important in the phenotypic regulation of smooth muscle 
ceils from the normally quiescent contractile to the syn- 
thetic and also to the proliferative phase. Although a 
considerable amount of information is available about the 
regulatory properties of growth factors on the basis of many 
in vitro studies in animal and human neonatal smooth 
muscle cells, very little work is available in human tissue-- 
adult human tissue. In this excellent work, the authors 
attempt to present a more complete picture by using human 
adult smooth muscle ceils harvested from arteries from 
organ transplant donors. However, these human adult 
smooth muscle cells may not necessarily be a true pheno- 
typic representation f smooth muscle cells found in dis- 
eased human arteries, which leads to the first of my three 
questions. Have the authors performed similar experiments 
with smooth muscle cells harvested from unaffected non- 
aortic sites and diseased human arteries? Will the phenotypic 
regulation be the same in normal as in abnormal arteries? 
Based on the author's findings, TGF-~I could be used to 
inhibit smooth muscle cell proliferation. However, Majesld 
and collaborators have recently reported that infusing 
TGF-~I after balloon catheter injury to rabbit carotid artery 
increased smooth muscle cell proliferation rather than 
inhibiting it. How do you explain this discrepancy between 
in vivo and in vitro results? Thirdly, a number of studies of 
smooth muscle cells have determined that TGF-[31 has a 
bimodal effect on the growth. In these animal in vitro 
studies, high doses--more than 10 ng/ml of TGF-131--had 
an antiproliferative effect, whereas low doses--less than 1 
ng/ml - -had a proliferative ffect. Have the authors seen 
these opposing biologic dose-related responses in human 
smooth muscle cell growth at a low concentration of 
TGF-]31? We are looldng forward to further work from this 
group in an attempt o better understand and ultimately 
control smooth muscle cell proliferation i diseased human 
arteries. 
Dr. Brian G. Halloran. You have raised some impor- 
tant issues. The first was "Have we actually analyzed smooth 
muscle cells derived from the nonaortic sites?" No, we have 
not. All our smooth muscle cells are derived from the aorta, 
primarily from the infrarenal aorta, although we do perform 
separate studies on smooth muscle cells derived from the 
proximal thoracic aorta. 
The other part of that question was "Have we also 
analyzed smooth muscle cells from diseased aorta?" Not 
specifically. Although aortas that we get from transplant 
patients are considered to be normal, we know that there is 
a degree of histologic atherosclerosis present in essentially 
all of them. Atherosclerosis would be increased in regard to 
the age of the transplant donor. In one respect, here is some 
baseline subclinical disease in these aortas. We would still 
consider them to be essentially normal compared with a true 
clinical atherosclerotic aorta. Would those results be differ- 
ent were we to do that? I think it would be difficult to 
determine if there would be a change in the expression of 
collagen. What we have seen is that collagen is highly 
expressed in smooth muscle cells at baseline. We were 
impressed by the relative lack of stimulation of collagen by 
TGF-[31 (in essence a 30% increase), whereas in many other 
cell types there are fold increases in type I collagen. In 
diseased smooth muscle cells, it may be difficult o detect a
large increase in type I collagen expression because in 
normal smooth muscle cells there is essentially a minimal 
increase. 
The other issues raised were regarding other experi- 
menters using TGF antibody to inhibit intimal hyperplasia. 
I think what we can conclude is that because our studies are 
primarily focused on the human arterial smooth muscle 
cells, there may actually be differences insmooth muscle cell 
lineages on the basis of species. We have tried to duplicate 
the experimental conditions that Drs. Majak and Ross have 
published as far as smooth muscle cell confluence and their 
rate of proliferation. When we try to control all those things, 
we still see that there is no stimulation of proliferation with 
TGF-~I, and we would have to conclude that this is the 
result of human arterial smooth muscle cells. In support of 
that, Dr. Kent in Boston, who is using venous smooth 
muscle cells, has shown TGF-]31 to be an inhibitor of 
proliferation. 
Dr. David Brenin (Chicago, Ill.). I just have a couple 
of questions about he quantitative RT-PCR. As you know, 
quantitative RT-PCR is a very sensitive and perhaps con- 
troversial technique. What ldnd ofcontr01s did you use, and 
did you back up everything with Northerns and dot blots? 
Dr. Halloran. Actually, for this experiment, we did use 
Northerns and dot blots to further substantiate changes in 
a quantitative manner. There obviously are inherent prob- 
lems with RT-PCR that you can try to standardize with an 
internal housekeeping gene, GAPDH, as we showed on 
these blots. Recently, we have been able to perfect he use of 
true quantitative RT-PCR with true internal standards that 
are amplified at the same time. However, we did not 
perform that type of analysis on the RNA from these 
studies. 
